一个数字平台,以优化指南导向的心力衰竭治疗:AIM-POWER试验的理由和设计
Adam D Devore1, Jiecheng Xie2, Leigh Etters2
1Duke Clinical Research Institute and Department of Medicine, Duke University School of Medicine, Durham, NC.
Journal of cardiac failure
|March 23, 2025
概括
像BiovitalsHF这样的数字工具在优化心力衰竭 (HF) 药物治疗方面表现有前途. 这项研究评估了其在改善减少射出分数 (HFrEF) 的HF患者的药理疗法的有效性.
科学领域:
- 心脏病学 心脏病学
- 数字健康数字健康
- 药理学 药理学是指药理学的学科.
背景情况:
- 心力衰竭 (HF) 患者面临高住院和死亡风险,部分原因是未充分利用指南导向医学治疗.
- 数字干预有可能及时启动和定位高频疗法,但需要严格的评估.
- 在AIM-POWER研究中,研究了一种用于HF管理的数字治疗 (DTx).
研究的目的:
- 评估BiovitalsHF DTx平台的安全性和有效性.
- 评估平台能够指导HFrEF患者药理疗法的最佳启动和定位的能力.
- 确定数字支持是否有助于提高对HF治疗指南的遵守.
主要方法:
- 纳入了122名具有症状的HFrEF患者 (LVEF ≤40%),这些患者在HF治疗中没有得到优化.
- 参与者被随机分为1:1接受BiovitalsHF支持的护理或以开放标签的方式接受常规护理.
- BiovitalsHF使用可穿戴式监视器和数字秤向临床医生提供治疗建议.
主要成果:
- 主要结局是从基线到90天的HF最佳药物治疗得分的变化.
- 通过BiovitalsHF平台收集了有关患者状况和治疗建议的数据.
- 临床医生对处方和定位的决定独立于平台的建议.
结论:
- 该AIM-POWER研究提供了对高频管理的数字干预措施的见解.
- 评估了BiovitalsHF在改善HFrEF患者药理疗法的使用和剂量的有效性.
- 结果将为数字健康策略在心血管保健中的更广泛应用提供信息.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
476
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
476
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
354
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
354
01:22Heart Failure Drugs: β-Blockers
299
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
299
01:22Heart Failure Drugs: Diuretics
309
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
309
01:17Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
121
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
121